In 1989 was created OrbiMed, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the New York.
Besides them, we counted 15 critical employees of this fund in our database.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the OrbiMed, startups are often financed by New Enterprise Associates, Kearny Venture Partners, Sequoia Capital. The meaningful sponsors for the fund in investment in the same round are Deerfield, Alta Partners, Topspin Partners. In the next rounds fund is usually obtained by Versant Ventures, Venrock, OUP (Osage University Partners).
Among the most popular portfolio startups of the fund, we may highlight Loxo Oncology, Receptos, Avanir Pharmaceuticals. Among the most popular fund investment industries, there are Biotechnology, Clinical Trials. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
Speaking about the real fund results, this VC is 22 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The typical startup value when the investment from OrbiMed is 100-500 millions dollars. Opposing the other organizations, this OrbiMed works on 6 percentage points more the average amount of lead investments. The top amount of exits for fund were in 2015. The fund is generally included in 13-24 deals every year.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Alterome Therapeutics | $132M | 03 Apr 2024 | San Diego, California, United States | ||
Mirador Therapeutics | $400M | 21 Mar 2024 | San Diego, California, United States | ||
Capstan Therapeutics | $175M | 20 Mar 2024 | San Diego, California, United States | ||
Sionna Therapeutics | $182M | 06 Mar 2024 | Natick, Massachusetts, United States | ||
ProfoundBio | $112M | 13 Feb 2024 | Suzhou, Jiangsu, China | ||
Noctrix Health | $40M | 16 Jan 2024 | San Francisco, California, United States | ||
OnCusp Therapeutics | $100M | 04 Jan 2024 | New York, New York, United States | ||
ENYO Pharma | $46M | 03 Jan 2024 | Lyon, Auvergne-Rhône-Alpes, France | ||
BlossomHill Therapeutics | $100M | 02 Jan 2024 | San Diego, California, United States |
– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.
– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Alterome Therapeutics | $132M | 03 Apr 2024 | San Diego, California, United States | ||
Mirador Therapeutics | $400M | 21 Mar 2024 | San Diego, California, United States | ||
Capstan Therapeutics | $175M | 20 Mar 2024 | San Diego, California, United States | ||
Sionna Therapeutics | $182M | 06 Mar 2024 | Natick, Massachusetts, United States | ||
ProfoundBio | $112M | 13 Feb 2024 | Suzhou, Jiangsu, China | ||
Noctrix Health | $40M | 16 Jan 2024 | San Francisco, California, United States | ||
OnCusp Therapeutics | $100M | 04 Jan 2024 | New York, New York, United States | ||
ENYO Pharma | $46M | 03 Jan 2024 | Lyon, Auvergne-Rhône-Alpes, France | ||
BlossomHill Therapeutics | $100M | 02 Jan 2024 | San Diego, California, United States |
